METHOD FOR TREATING CANCER
The present disclosure relates to pharmaceutical compositions comprising inhibitor(s) of human histone methyltransferase EZH2, and methods of cancer therapy using the EZH2 inhibitor(s).
1 . A method for treating an INI1-negative tumor comprising administering a therapeutically effective amount of an EZH2 inhibitor to a subject in need thereof, wherein the INI1-negative tumor is selected from a rhabdoid tumor of the kidney (RTK) and an atypical teratoid/rhabdoid tumor (ATRT).
2 . The method of claim 1 , wherein the INI1-negative tumor is rhabdoid tumor of the kidney (RTK).
3 . The method of claim 1 , wherein the IM1-negative tumor is atypical teratoid/rhabdoid tumor (ATRT).
4 .- 6 . (canceled)
7 . The method of claim 1 , wherein the EZH2 inhibitor is administered orally.
8 . The method of claim 1 , wherein the subject is a human being.
9 . The method of claim 1 , wherein the subject is younger than 18 years.
10 . The method of claim 19 , wherein the EZH2 inhibitor is Compound (A), having the following formula:
or a pharmaceutically acceptable salt thereof.
11 . The method of claim 1 , wherein the EZH2 inhibitor is administered to the subject at a dose of about 100 mg to about 3200 mg daily.
12 . The method of claim 1 , wherein the EZH2 inhibitor is administered to the subject at a dose of about 100 mg BID to about 1600 mg BID.
13 . The method of claim 1 , wherein the EZH2 inhibitor is administered to the subject at a dose of about 100 mg BID, 200 mg BID, 400 mg BID, 800 mg BID, or about 1600 mg BID.
14 . The method of claim 13 , wherein the EZH2 inhibitor is administered to the subject at a dose of 800 mg BID.
15 . The method of claim 1 , wherein the EZH2 inhibitor is selected from the group consisting of
and pharmaceutically acceptable salts thereof.
16 . The method of claim 15 , wherein the EZH2 inhibitor is:
or a pharmaceutically acceptable salt thereof.